SCHEMBL548514

SCHEMBL548514

CCCCCCCCCCCC/C=C/[C]=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.54
TRPV1 Q8NER1 1/20 0.54
TSHR P16473 1/20 0.48
TERT O14746 3/20 0.47
PTPN1 P18031 3/20 0.47
PPARG P37231 3/20 0.47
PPARD Q03181 3/20 0.47
PPARA Q07869 3/20 0.47
CYP1A2 P05177 2/20 0.47
MAPT P10636 2/20 0.47
CYP2C19 P33261 2/20 0.47
BLM P54132 2/20 0.47
HSD17B10 Q99714 2/20 0.47
FABP4 P15090 2/20 0.47
KMT2A Q03164 2/20 0.47
GMNN O75496 1/20 0.47
USP2 O75604 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL158907 1.00 FAAH (0.54) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL2163660 1.00 FAAH (0.54) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL2163401 1.00 FAAH (0.54) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL16431159 1.00 FAAH (0.54) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL910497 1.00 FAAH (0.54) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL548521 1.00 FAAH (0.54) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL1240474 1.00 FAAH (0.54) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL158906 1.00 FAAH (0.54) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL9696115 1.00 FAAH (0.54) FAAHTRPV1TSHRTERTPTPN1
SCHEMBL415112 1.00 FAAH (0.54) FAAHTRPV1TSHRTERTPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4368657-A1 PH-RESPONSIVE LIPID DERIVATIVE NOF Corporation (JP) 2024-05-15 EP disclosed
US-20240132628-A1 OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE NEUBASE THERAPEUTICS, INC. 2024-04-25 US disclosed
EP-4332146-A1 POLYTHIOPHENE COMPOUND AND CONDUCTIVE MATERIAL COMPOSITION OSAKA UNIVERSITY (JP) 2024-03-06 EP disclosed
EP-4263491-A2 OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE NeuBase Therapeutics, Inc. (US) 2023-10-25 EP disclosed
US-20230242692-A1 COMPOSITION AND CURED PRODUCT TOKYO OHKA KOGYO CO., LTD. (JP) 2023-08-03 US disclosed
US-20230174985-A1 MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS NEUBASE THERAPEUTICS, INC. 2023-06-08 US disclosed
US-20230103631-A1 PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS SANOFI (FR) 2023-04-06 US disclosed
CN-115884982-A Peptides as selective GIP receptor agonists 赛诺菲 2023-03-31 CN disclosed
US-11603530-B2 Modified peptide nucleic acid compositions NEUBASE THERAPEUTICS, INC. (US) 2023-03-14 US disclosed
EP-4127228-A2 MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS NeuBase Therapeutics, Inc. (US) 2023-02-08 EP disclosed
US-20070142534-A1 Process for the preparation of polyolefin nanocomposites POLYMERS AUSTRALIA PTY. LIMITED (AU) 2007-06-21 US disclosed
WO-2007039435-A1 DISPERSING AGENTS IN COMPOSITES POLYMERS CRC LIMITED (AU) 2007-04-12 WO disclosed
EP-1575873-A1 PROCESS FOR THE PREPARATION OF POLYOLEFIN NANOCOMPOSITES Polymers Australia PTY Limited (AU) 2005-09-21 EP disclosed
WO-2004041721-A1 PROCESS FOR THE PREPARATION OF POLYOLEFIN NANOCOMPOSITES POLYMERS AUSTRALIA PTY. LIMITED (AU) 2004-05-21 WO disclosed
US-6562804-B2 For stimulating hair growth in a mammal KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-05-13 US disclosed
US-20020172657-A1 Hair-growing agent KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-11-21 US disclosed
EP-1232740-A2 Hair-growing agent KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-21 EP disclosed
US-4665201-A ANTITUMOR AGENTS SUNTORY, LIMITED (JP) 1987-05-12 US disclosed
EP-0080570-B1 AILANTHONE DERIVATIVES SUNTORY LIMITED (JP) 1986-12-17 EP disclosed
EP-0080570-A2 Ailanthone derivatives SUNTORY LIMITED (JP) 1983-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020172657-A1 Hair-growing agent PHOSPHO1, PLD1, SGMS1 FAAH 93/4885TRPV1 1722/4885TSHR 2886/4885
US-20230174985-A1 MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS TARDBP, SARNP, SNRPE FAAH 4761/4885TRPV1 4600/4885TSHR 1773/4885
US-11603530-B2 Modified peptide nucleic acid compositions TARDBP, SARNP, SNRPE FAAH 4761/4885TRPV1 4600/4885TSHR 1773/4885
US-20230103631-A1 PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS GIPR, GLP1R, GPR119 FAAH 555/4885TRPV1 117/4885TSHR 145/4885
US-20240132628-A1 OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE SMN1; SMN2, POLRMT, TARDBP FAAH 3939/4885TRPV1 4376/4885TSHR 2368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.